Symphogen's Series D - II Round

Symphogen raised a round of funding on January 19, 2007. Investors include Gilde Healthcare Partners.

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the fr…

Articles about Symphogen's Series D - II Round: